BEVERLY, MA, May 24, 2010 -- Cellceutix Corporation (OTCBB: CTIX), a bio-pharmaceutical company that develops small molecules to treat cancer, autism and inflammatory disease, today announced that it has concluded agreements with PharPoint Reasearch for Phase 1 data management and statistical analysis and with Medical Research Consulting Services for Phase 1 clinical monitoring.
Cellceutix Corporation closed at $0.45 Friday, trading 11,900 shares.
Cellceutix Signs Agreements for KevetrinTM Phase 1 Support; Company Continues to Advance Kevetrin
Toward Human Studies Targeting Drug Resistant Cancers
About Cellceutix
Cellceutix Corporation is a preclinical cancer, autism and anti-inflammatory drug developer. Cellceutix owns the rights to eight drug compounds, including Kevetrin, which it is developing as a treatment for certain cancers, and KM-391, which it is developing for the treatment of autism. More information is available on the Cellceutix web site at cellceutix.com.
For additional penny stock news, tools and tips visit http://stockprofiler.us/?action=main.market_news
-------------------------------------------
SAN FRANCISCO, CA, May 24, 2010 -- AmStem International (OTCBB: AMST), an international biotechnology company operating in the high-tech field of stem cell based therapy with emphasis on regenerative medicine and treatments, announced today that it has retained the services of Hawk Associates for strategic investor relations.
AmStem International closed at $0.06 Friday, trading 164,550 shares.
AmStem Corporation Retains Hawk Associates for Strategic Investor Relations
About AmStem International
AmStem is an international biotechnology company operating in the high-tech field of stem cell-based therapy with emphasis on regenerative medicine and treatments. The company, which operates one of the world's largest cord blood banks, is a pioneer in both medical and cosmetic treatments using stem cells isolated from human umbilical cord blood and nurtured to multipotent stem cells. Actively pursuing new applications in both medicine and cosmetics, AmStem has successfully treated patients with a number of serious diseases and has numerous clinical trials in progress. Its main cosmetic product is the facial cream SteMixx.
For additional penny stock news, tools and tips visit http://stockprofiler.us/?action=main.market_news
-------------------------------------------
Membership with access to enhanced stock investing tools is now FREE! Claim yours at http://www.stockprofiler.us/Register
Stay connected with StockProfiler.US – Fan up with us on Facebook (keyword: StockProfiler.US) or follow us on Twitter at http://twitter.com/StockProfilerUS
View free penny stock company videos and product reviews at our YouTube channel. Visit http://www.youtube.com/StockProfilerUS
-------------------------------------------
About StockProfiler.US:
StockProfiler.US is a media source for publicly traded penny stock companiesand investors to come together and discover market opportunities. Public companies can effectively broadcast their message to a targeted audience who come to StockProfiler.US seeking an advantage by discovering companies in their startup phase or ones who have yet to be discovered by the investment community.
Call us at (603) 424-4420 or email info@stockprofiler.us
-------------------------------------------Please Note: All news contained herein has been previously issued by the companies mentioned in this release, and is the property of each company, respectively. All news is edited for content. The companies that are discussed in this opinion have not approved the statements made in this opinion.
This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities.
Stock Profiler.US, LLC's News Division includes but is not limited to: http://www.stockprofiler.us, http://www.associatesfortune.com,http://www.fastmoneytalk.com, http://www.markettelegraph.com,http://www.thewallstreetleader.com, and http://www.daytradersdigest.com.
Stock Profiler.US, LLC has been compensated for services rendered; Stock Profiler.US, LLC is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter.
To view full disclaimers and terms of use, go to http://www.stockprofiler.us/Disclaimer
-------------------------------------------
Keywords: penny stock, penny stock news, penny stock alerts, penny stock updates, penny stock news updates, penny stock profile
Posts
No comments:
Post a Comment